Prime Medicine, Inc. EBIT

EBIT of PRME for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT growth rates and interactive chart. Earnings before interest and taxes is an indicator of a company's profitability. One can calculate it as revenue minus all expenses, excluding tax and interest. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes. It is the amount of profit that a company earns before interest on debt and taxes are paid.

Highlights and Quick Summary

  • EBIT for the quarter ending September 30, 2023 was $-51.5 Million (a 13.7% increase compared to previous quarter)
  • Year-over-year quarterly EBIT increased by 33.02%
  • Annual EBIT for 2022 was $-117 Million (a 37.96% increase from previous year)
  • Annual EBIT for 2021 was $-84.5 Million (a 8963.73% increase from previous year)
  • Twelve month EBIT ending September 30, 2023 was $-175 Million (a 12.72% increase compared to previous quarter)
  • Twelve month trailing EBIT increased by 50.53% year-over-year
Trailing EBIT for the last four month:
30 Sep '23 30 Jun '23 31 Mar '23 31 Dec '22
$-175 Million $-156 Million $-137 Million $-117 Million
Visit stockrow.com/PRME for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT of Prime Medicine, Inc.

Most recent EBITof PRME including historical data for past 10 years.

Interactive Chart of EBIT of Prime Medicine, Inc.

Prime Medicine, Inc. EBIT for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2023 $-51.46 $-45.26 $-40.03 – –
2022 $-38.69 $-31.66 $-26.31 $-19.9 $-116.54
2021 – – – $-10.43 $-84.47
2020 – – – – $-0.93

Business Profile of Prime Medicine, Inc.

Sector: Healthcare
Industry: Biotechnology
© stockrow.com